CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $120.00 at Truist Financial

CRISPR Therapeutics (NASDAQ:CRSP) had its price objective upped by Truist Financial from $100.00 to $120.00 in a research note published on Wednesday morning,Benzinga reports. Truist Financial currently has a buy rating on the stock.

Several other analysts have also issued reports on CRSP. Chardan Capital restated a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Bank of America reduced their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Barclays lifted their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday. HC Wainwright started coverage on shares of CRISPR Therapeutics in a research note on Monday, February 3rd. They issued a “buy” rating and a $65.00 price objective for the company. Finally, Royal Bank of Canada dropped their target price on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $76.11.

CRISPR Therapeutics Stock Up 9.3 %

Shares of NASDAQ CRSP opened at $43.30 on Wednesday. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10. The business has a fifty day simple moving average of $42.06 and a 200-day simple moving average of $46.25.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. Equities research analysts forecast that CRISPR Therapeutics will post -5.08 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Darwin Wealth Management LLC acquired a new stake in CRISPR Therapeutics in the 3rd quarter valued at $43,000. Highline Wealth Partners LLC bought a new position in shares of CRISPR Therapeutics in the 4th quarter valued at about $39,000. Western Pacific Wealth Management LP boosted its position in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the last quarter. Finally, Eastern Bank bought a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $70,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.